Scalper1 News
Clovis Technology (CLVS) stock rose Monday after Goldman Sachs upgraded its rating and sharply raised its stock price target on the developer of anti-cancer treatments. Goldman upgraded Clovis to a buy from neutral and increased the price target to 117 from 68. Clovis stock was up nearly 13% in late-afternoon trading on the stock market today, at a 13-month high near 88. Clovis stock is up more than 55% this year The biopharmaceutical company is Scalper1 News
Scalper1 News